Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
- 23 July 2004
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (5) , 475-482
- https://doi.org/10.1007/s00198-004-1698-y
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent FracturesArchives of internal medicine (1960), 2004
- Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) StudyJournal of Bone and Mineral Research, 2004
- Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year StudyJournal of Bone and Mineral Research, 2004
- The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 2004
- Executive SummaryJournal of Clinical Densitometry, 2004
- Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trialBone, 2003
- The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- Vitamin D3and Calcium to Prevent Hip Fractures in Elderly WomenNew England Journal of Medicine, 1992